| 臺大學術典藏 |
2021-08-06T03:59:35Z |
Group Report Contest Enhances Problem-Based Learning
|
Jeng-Yi Shieh; Chien-An Yao; CHIUN HSU; Shan-Chwen Chang; Fen-Yu Tseng |
| 臺大學術典藏 |
2021-08-06T03:52:20Z |
The Learning Experiences of Medical and Pharmacy Students Participating in Interdisciplinary Problem-Based Small-group Discussions
|
Chia-Hsuin Chang; CHIUN HSU; Chao-Chi Ho; Hsiu-Ying Wu; Ai-Tzu Li; Fen-Yu Tseng |
| 臺大學術典藏 |
2021-08-06T03:45:52Z |
Students' Perspective on the Key Elements and Effectiveness of Problem-based Learning Group Discussion
|
Chia-Hsuin Chang; CHIUN HSU; Chao-Chi Ho; Hsiu-Ying Wu; Ai-Tzu Li; Fen-Yu Tseng |
| 臺大學術典藏 |
2021-08-06T03:38:36Z |
Gap in the Intensity of End-of-Life Care between Younger and Older Taiwanese Adult Cancer Patients may not Reflect Younger Patients' Preferences
|
Siew-Tzuh Tang; Tsang-Wu Liu; Jyh-Ming Chow; Chang-Fang Chiu; CHIUN HSU; Li-Ni Liu; Su-Ching Kuo |
| 臺大學術典藏 |
2021-08-06T03:26:51Z |
Targeted Therapy for Hepatocellular Carcinoma
|
CHIUN HSU; Ying-Chun Shen; Ann-Lii Cheng |
| 臺大學術典藏 |
2021-07-15T05:31:54Z |
Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives
|
Su, Yung Yeh; Li, Chia Chen; Lin, Yih Jyh; CHIUN HSU |
| 臺大學術典藏 |
2021-07-15T05:31:28Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Chia-Lang Hsu; DA-LIANG OU; Bai, Li Yuan; Chen, Chia Wei; Lin, Li; Huang, Shiu Feng; ANN-LII CHENG; YUNG-MING JENG; CHIUN HSU |
| 臺大學術典藏 |
2021-05-13T06:17:53Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang, Fan-Chi; Chen, Tom Wei-Wu; Huang, Thomas Tao-Min; Lin, Wei-Chou; Liu, Jia-Sin; WEN-CHIH CHIANG; Chen, Yung-Ming; CHIUN HSU; Yeh, Kun-Huei; Chu, Tzong-Shinn |
| 臺大學術典藏 |
2021-05-13T01:56:55Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang, Fan-Chi; Chen, Tom Wei-Wu; Huang, Thomas Tao-Min; Lin, Wei-Chou; Liu, Jia-Sin; Chiang, Wen-Chih; YUNG-MING CHEN; CHIUN HSU; Yeh, Kun-Huei; Chu, Tzong-Shinn |
| 臺大學術典藏 |
2021-04-21T23:30:44Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
DA-LIANG OU; Chen, Chia Wei; Chia-Lang Hsu; Chung, Chih Hung; Feng, Zi Rui; Lee, Bin Shyun; ANN-LII CHENG; Yang, Muh Hwa; CHIUN HSU |
| 臺大學術典藏 |
2021-03-14T23:24:21Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang, Fan Chi; Chen, Tom Wei Wu; Huang, Thomas Tao Min; WEI-CHOU LIN; Liu, Jia Sin; WEN-CHIH CHIANG; YUNG-MING CHEN; Chiun Hsu; KUN-HUEI YEH; TZONG-SHINN CHU |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Chiun Hsu;Cheng A.-L.; Lu L.-C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.;Liu T.-H.;Chiun Hsu;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.; Shao Y.-Y.; Liu T.-H.; Chiun Hsu; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.;Chiun Hsu;Jeng Y.-M.;Hu F.-C.;Pan H.-W.;Wu Y.-M.;Hsu H.-C.;Cheng A.-L.; Lin Z.-Z.; Chiun Hsu; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:47Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chiun Hsu;Yoshino T.;Douillard J.-Y.; Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Shen Y.-C.; Tabernero J.; Yen Y.; Chiun Hsu; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.;Wang S.-Y.;Lin S.-M.;Chen K.-Y.;Tseng J.-H.;Ho M.-C.;Lee R.-C.;Liang P.-C.;Liao L.-Y.;Huang K.-W.;Hu J.-T.;Liang J.-D.;Kee K.-M.;Lin C.-L.;Wang C.-K.;Lu S.-N.;Wang J.-H.;Lee W.-C.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Wang C.-C.;Wang T.-E.;Chuang P.-H.;Dai C.-Y.;Chiun Hsu;Chen S.-C.;Hsieh C.-H.;Diagnosis Group, Systemic Therapy Group; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Chiun Hsu; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Corrigendum to Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Dela Cruz C.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.;Shao Y.-Y.;Chiun Hsu;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; Shao Y.-Y.; Chiun Hsu; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.;Tsai K.K.;Hsiao C.-F.;Yang S.-H.;Hsiao H.-H.;Shen W.-C.;Chiun Hsu;Lin Y.-L.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; Yang S.-H.; Hsiao H.-H.; Shen W.-C.; Chiun Hsu; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.;Kang Y.-K.;Kim T.-Y.;El-Khoueiry A.B.;Santoro A.;Sangro B.;Melero I.;Kudo M.;Hou M.-M.;Matilla A.;Tovoli F.;Knox J.J.;Ruth He A.;El-Rayes B.F.;Acosta-Rivera M.;Lim H.-Y.;Neely J.;Shen Y.;Wisniewski T.;Anderson J.;Chiun Hsu; Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T02:09:11Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.;Chiun Hsu;Chan S.L.;Choo S.-P.;Kudo M.; Cheng A.-L.; Chiun Hsu; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
|
Mehnert J.M.;Bergsland E.;O??Neil B.H.;Santoro A.;Schellens J.H.M.;Cohen R.B.;Doi T.;Ott P.A.;Pishvaian M.J.;Puzanov I.;Aung K.L.;Chiun Hsu;Le Tourneau C.;Hollebecque A.;?Lez E.;Tamura K.;Gould M.;Yang P.;Stein K.;Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; Chiun Hsu; Le Tourneau C.; Hollebecque A.; ?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chiun Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Chiun Hsu; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
|
Chen M.-H.;Chou W.-C.;Hsiao C.-F.;Jiang S.S.;Tsai H.-J.;Liu Y.-C.;Chiun Hsu;Shan Y.-S.;Hung Y.-P.;Hsich C.-H.;Chiu C.-H.;Liu T.-C.;Cho S.-F.;Liu T.-W.;Chao Y.; Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; Chiun Hsu; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:21Z |
Novel systemic therapy for hepatocellular carcinoma
|
Dong Y.;Liu T.-H.;Yau T.;Chiun Hsu; Dong Y.; Liu T.-H.; Yau T.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T01:45:21Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chiun Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Chiun Hsu; Cheng A.-L.; Lee R.-C.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:20Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Lin C.-C.;Yang T.-S.;Yen C.-J.;Cheng R.;Liu J.;Chiun Hsu; Lin C.-C.; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T01:45:20Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.;Chen M.-H.;Yang S.-H.;Chiun Hsu;Yen C.-J.;Tsou H.-H.;Su Y.-Y.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Chen M.-H.; Yang S.-H.; Chiun Hsu; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-18T09:11:58Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
YI-PING HUNG; YU-YUN SHAO; Chiun Hsu; CHIH-HUNG HSU; Lee, Jan Mou; Yang, Muh Hwa; Chao, Yee |
| 臺大學術典藏 |
2021 |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Tseng J.-H.; Ho M.-C.; Liao L.-Y.; Liang J.-D.; Wang C.-K.; Lee W.-C.; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Lee R.-C.; Liang P.-C.; Huang K.-W.; Hu J.-T.; Kee K.-M.; Lin C.-L.; Lu S.-N.; Wang J.-H.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2020-08-14T01:27:01Z |
Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma
|
Ou, Da-Liang;Lin, Yu-Yang;Hsu, Chia-Lang;Lin, Yin-Yao;Chen, Chia-Wei;Yu, Jhang-Sian;Shi-Chuen Miaw;Hsu, Ping-Ning;Cheng, Ann-Lii;Chiun Hsu; Ou, Da-Liang; Lin, Yu-Yang; Hsu, Chia-Lang; Lin, Yin-Yao; Chen, Chia-Wei; Yu, Jhang-Sian; SHI-CHUEN MIAW; Hsu, Ping-Ning; Cheng, Ann-Lii; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:33Z |
Surgical resection for recurrent hepatocellular carcinoma: Prognosis and analysis of risk factors
|
Hu R.-H.;Lee P.-H.;Yu S.-C.;Dai H.-C.;Sheu J.-C.;Lai M.-Y.;Chiun Hsu;Chen D.-S.; Hu R.-H.; Lee P.-H.; Yu S.-C.; Dai H.-C.; Sheu J.-C.; Lai M.-Y.; Chiun Hsu; Chen D.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: Does histologic evidence of MALT affect chemotherapy response?
|
Chiun Hsu;Chen C.-L.;Chen L.-T.;Liu H.-T.;Chen Y.-C.;Jan C.-M.;Liu C.-S.;Cheng A.-L.; Chiun Hsu; Chen C.-L.; Chen L.-T.; Liu H.-T.; Chen Y.-C.; Jan C.-M.; Liu C.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach
|
Cheng A.-L.; Chen Y.-C.; Chen L.-T.; Chiang I.-P.; Chen C.-L.; Chiun Hsu; Liu H.-T.; Liu H.-T.;Chiun Hsu;Chen C.-L.;Chiang I.-P.;Chen L.-T.;Chen Y.-C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome
|
Chiun Hsu;Lin M.-T.;Tang J.-L.;Tien H.-F.;Wang C.-H.;Chen Y.-C.; Chiun Hsu; Lin M.-T.; Tang J.-L.; Tien H.-F.; Wang C.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
|
Liu M.-Y.;Chiun Hsu;Lin J.-T.;Yeh K.-H.;Cheng A.-L.; Cheng A.-L.; Yeh K.-H.; Lin J.-T.; Chiun Hsu; Liu M.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Chiun Hsu; Yeh K.-H.; Hong R.-L.; Yang C.-H.; Lin M.-T.; Chen Y.-C.; Cheng A.-L.; Chiun Hsu;Yeh K.-H.;Hong R.-L.;Yang C.-H.;Lin M.-T.;Chen Y.-C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:31Z |
HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity
|
Chiun Hsu;Huang C.-L.;Hsu H.-C.;Lee P.-H.;Wang S.-J.;Cheng A.-L.; Chiun Hsu; Huang C.-L.; Hsu H.-C.; Lee P.-H.; Wang S.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Chiun Hsu;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Yang P.-C.;Perng R.-P.; Perng R.-P.; Yang P.-C.; Luh K.T.; Huang M.H.; Chen Y.M.; Chiang S.C.; Liu M.Y.; Cheng A.L.; Chiun Hsu; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Yang C.H. |
| 臺大學術典藏 |
2020-04-10T12:51:30Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma
|
Chiun Hsu;Huang C.-S.;Chao T.-Y.;Lu Y.-S.;Bu C.-F.;Chen M.M.;Chang K.-J.;Cheng A.-L.; Chiun Hsu; Huang C.-S.; Chao T.-Y.; Lu Y.-S.; Bu C.-F.; Chen M.M.; Chang K.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13
|
Chie W.-C.;Yang C.-H.;Chiun Hsu;Yang P.-C.; Chie W.-C.; Yang C.-H.; Chiun Hsu; Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Chiun Hsu;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma
|
Yang P.-M.; Wu C.-Y.; Chen L.-T.; Chen C.-N.; Chiun Hsu; Chiun Hsu;Chen C.-N.;Chen L.-T.;Wu C.-Y.;Yang P.-M.;Lai M.-Y.;Lee P.-H.;Cheng A.-L.; Lai M.-Y.; Lee P.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:28Z |
Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factors
|
Chiun Hsu;Chen C.-N.;Chen L.-T.;Wu C.-Y.;Hsieh F.-J.;Cheng A.-L.; Chiun Hsu; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Hsieh F.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:28Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
Kuo S.-H.;Yang C.-H.;Yu C.-J.;Chiun Hsu;Cheng A.-L.;Yang P.-C.; Kuo S.-H.; Yang C.-H.; Yu C.-J.; Chiun Hsu; Cheng A.-L.; Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:28Z |
Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
|
Chen J.-Y.; Cheng A.-L.; Shen Y.-C.; Chiun Hsu; Shen Y.-C.;Chiun Hsu;Chen J.-Y.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:27Z |
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate
|
Lin C.-H.;Yen R.-F.;Jeng Y.-M.;Tzen C.-Y.;Chiun Hsu;Hong R.-L.; Lin C.-H.; Yen R.-F.; Jeng Y.-M.; Tzen C.-Y.; Chiun Hsu; Hong R.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:27Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.;Yang C.-H.;Yu C.-J.;Shih J.-Y.;Chiun Hsu;Yang P.-C.; Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chiun Hsu; Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: Implication from age-period-cohort analysis
|
Chiun Hsu;Shen Y.-C.;Cheng C.-C.;Hong R.-L.;Chang C.-J.;Cheng A.-L.; Chiun Hsu; Shen Y.-C.; Cheng C.-C.; Hong R.-L.; Chang C.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Chen L.-T.; Shiah H.-S.;Cheng A.-L.;Chiun Hsu;Hsu C.-H.;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Chiun Hsu; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J. |
